AKT1 is altered in 1.31% of squamous cell lung carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

AKT2 is altered in 3.32% of squamous cell lung carcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

AKT3 is altered in 0.98% of squamous cell lung carcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ALK is altered in 5.71% of squamous cell lung carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ARAF is altered in 1.89% of squamous cell lung carcinoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is altered in 4.98% of squamous cell lung carcinoma patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATM status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

ATR is altered in 6.18% of squamous cell lung carcinoma patients [2].

ATR is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

BARD1 is altered in 1.6% of squamous cell lung carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

BCL2L11 is altered in 0.66% of squamous cell lung carcinoma patients [2].

BCL2L11 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2L11 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 1.85% of squamous cell lung carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 4 clinical trials for squamous cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRAF status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

BRCA1 is altered in 4.85% of squamous cell lung carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

BRCA2 is altered in 5.63% of squamous cell lung carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

BRIP1 is altered in 2.19% of squamous cell lung carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRIP1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CCND1 is altered in 8.92% of squamous cell lung carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

CCND2 is altered in 2.55% of squamous cell lung carcinoma patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

CCND3 is altered in 0.61% of squamous cell lung carcinoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

CDK12 is altered in 1.72% of squamous cell lung carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

CDK4 is altered in 1.6% of squamous cell lung carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

CDK6 is altered in 1.09% of squamous cell lung carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

CHEK1 is altered in 0.98% of squamous cell lung carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

CHEK2 is altered in 2.05% of squamous cell lung carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

CRKL is altered in 1.3% of squamous cell lung carcinoma patients [2].

CRKL is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 6.88% of squamous cell lung carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 4 clinical trials for squamous cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain EGFR status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ERBB2 is altered in 2.04% of squamous cell lung carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

FANCA is altered in 3.89% of squamous cell lung carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCA status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCB is altered in 3.06% of squamous cell lung carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCB status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCC is altered in 0.66% of squamous cell lung carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCC status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCD2 is altered in 3.78% of squamous cell lung carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCD2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCE is altered in 2.34% of squamous cell lung carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCF is altered in 0.69% of squamous cell lung carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCF status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCG is altered in 0.81% of squamous cell lung carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCG status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCI is altered in 5.08% of squamous cell lung carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCI status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCL is altered in 1.37% of squamous cell lung carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCL status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FANCM is altered in 6.12% of squamous cell lung carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCM status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

FGF1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF10 is altered in 2.08% of squamous cell lung carcinoma patients [2].

FGF10 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF14 is altered in 0.52% of squamous cell lung carcinoma patients [2].

FGF14 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF19 is altered in 9.85% of squamous cell lung carcinoma patients [2].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF23 is altered in 3.92% of squamous cell lung carcinoma patients [2].

FGF23 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF3 is altered in 11.46% of squamous cell lung carcinoma patients [2].

FGF3 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF4 is altered in 10.03% of squamous cell lung carcinoma patients [2].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF4 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF5 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF6 is altered in 4.17% of squamous cell lung carcinoma patients [2].

FGF6 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 8.86% of squamous cell lung carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FGFR1 status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (1 open) [3].

FGFR2 is altered in 1.39% of squamous cell lung carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [3].

FGFR3 is altered in 2.92% of squamous cell lung carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [3].

FGFR4 is altered in 0.96% of squamous cell lung carcinoma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HGF is altered in 3.19% of squamous cell lung carcinoma patients [2].

HGF is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [3].

HRAS is altered in 0.93% of squamous cell lung carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

KEAP1 is altered in 12.57% of squamous cell lung carcinoma patients [2].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

KRAS is altered in 4.45% of squamous cell lung carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 7 clinical trials for squamous cell lung carcinoma, of which 4 are open and 3 are closed. Of the trials that contain KRAS status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K1 is altered in 0.59% of squamous cell lung carcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is altered in 0.85% of squamous cell lung carcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 1.04% of squamous cell lung carcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is altered in 2.33% of squamous cell lung carcinoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is altered in 1.13% of squamous cell lung carcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MCPH1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

MET is altered in 3.25% of squamous cell lung carcinoma patients [2].

MET is an inclusion eligibility criterion in 4 clinical trials for squamous cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MET status and squamous cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) and 1 is no phase specified (1 open) [3].

MRE11A is altered in 1.15% of squamous cell lung carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MRE11A status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

MTOR is altered in 3.85% of squamous cell lung carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 1.12% of squamous cell lung carcinoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

NF1 is altered in 9.57% of squamous cell lung carcinoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NFE2L2 is altered in 15.79% of squamous cell lung carcinoma patients [2].

NFE2L2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NFE2L2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NRAS is altered in 0.87% of squamous cell lung carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

NTRK1 is altered in 3.7% of squamous cell lung carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NTRK2 is altered in 1.28% of squamous cell lung carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 5.94% of squamous cell lung carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.28% of squamous cell lung carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

PDGFRA is altered in 5.71% of squamous cell lung carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 16.64% of squamous cell lung carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [3].

PIK3CB is altered in 3.68% of squamous cell lung carcinoma patients [2].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CG is altered in 4.91% of squamous cell lung carcinoma patients [2].

PIK3CG is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is altered in 2.71% of squamous cell lung carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is altered in 1.76% of squamous cell lung carcinoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 9.73% of squamous cell lung carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (1 open) [3].

RAD50 is altered in 1.02% of squamous cell lung carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAD51 is altered in 0.55% of squamous cell lung carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAD51B is altered in 0.69% of squamous cell lung carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAD51C is altered in 0.75% of squamous cell lung carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51C status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAD51D is altered in 0.61% of squamous cell lung carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAD54L is altered in 1.09% of squamous cell lung carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

RAF1 is altered in 0.53% of squamous cell lung carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RET is altered in 3.75% of squamous cell lung carcinoma patients [2].

RET is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

RICTOR is altered in 4.43% of squamous cell lung carcinoma patients [2].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RICTOR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

RNF43 is altered in 0.91% of squamous cell lung carcinoma patients [2].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is altered in 9.1% of squamous cell lung carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is altered in 0.96% of squamous cell lung carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RPA1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RPTOR is altered in 3.26% of squamous cell lung carcinoma patients [2].

RPTOR is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RPTOR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SLX4 is altered in 2.44% of squamous cell lung carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SLX4 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [3].

SRC is altered in 1.14% of squamous cell lung carcinoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is altered in 2.59% of squamous cell lung carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 75.72% of squamous cell lung carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for squamous cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

TSC1 is altered in 3.51% of squamous cell lung carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 3.97% of squamous cell lung carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].